Moschos, Stergios J. http://orcid.org/0000-0002-8943-0845
Sandhu, Shahneen
Lewis, Karl D.
Sullivan, Ryan J.
Puzanov, Igor
Johnson, Douglas B.
Henary, Haby A.
Wong, Hansen
Upreti, Vijay V.
Long, Georgina V.
Flaherty, Keith T.
Funding for this research was provided by:
Amgen
Article History
Received: 12 February 2022
Accepted: 26 April 2022
First Online: 30 May 2022
Declarations
:
: The study was approved by the institutional review board of each participating academic institution. The study was performed in line with the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all individual participants included in the study.
: Consent to publish has been received from all individual participants included in the study
: HAH, HW, VVU are employees of Amgen Inc, and may own stock/stock options in the company. DBJ has served on advisory boards or as a consultant for Bristol-Myers Squibb (BMS), Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck Sharp & Dohme (MSD), Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, and Targovax, and has received research funding from BMS and Incyte. RJS has served as consultant and/or advisory boards for Asana Biosciences, AstraZeneca, BMS, Eisai, Iovance, MSD, Novartis, Oncosec, Pfizer, Replimune and has received research funding from Amgen and Merck. SS has served on advisory boards for BMS, Jansen, MSD, Novartis, and Astra Zeneca and has received research funding from Genentech, MSD, Merck Serono, Novartis and Amgen. GVL has served as consultant advisor or on advisory boards for Aduro Biotech, Agenus, Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Evaxion, Hexel AG, Highlight Therapeutics, MSD, Novartis, OncoSec, Pierre Fabre, QBiotics, Regeneron, Specialised Therapeutics. KTF has served on the board of directors of Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, Kinnate Pharmaceuticals and Scorpion Therapeutics; Corporate Advisory Board of X4 Pharmaceuticals; has served on the advisory boards of PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, Vibliome, and ALX Oncology; has served as a consultant to Elli Lilly and Company, Novartis, Genentech, BMS, MSD, Takeda, Verastem, Boston Biomedical, Pierre Fabre, Debiopharm; and has received research funding from Novartis and Sanofi.
: Written informed consent was obtained from all individual participants included in the study.
: see Competing interests in the Author Declarations Section.